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clinical snippets
Melanoma Marker
Sheen and colleagues reported 
that IGF II mRNA-binding 
partner 3 (IMP-3), which 
is expressed in malignant 
melanomas but not in benign 
melanocytic nevi, promotes 
the migration and invasion of 
melanoma cells via regulation 
of high-mobility group AT-hook 
2 (HMGA2). Moreover, IMP-3 
is a strong prognostic factor for 
melanoma, especially for acral 
lentiginous melanoma, which 
comprises 76% of melanoma 
cases. This new information 
illuminates IMP-3 and 
HMGA2 as potential targets 
for development of clinical 
treatments for metastatic 
melanoma, which is generally 
intractable and yields a poor 
prognosis. See page 1065
Survive and Advance
Inactivating germline 
mutations of the BRCA1-
associated protein 1 (BAP1) 
gene have been identified in 
families prone to cutaneous 
and ocular melanoma. Kumar 
and colleagues uncovered 
a growth-sustaining role 
for BAP1 in cutaneous 
melanoma cells. Depletion of 
BAP1 reduced proliferation, 
enhanced apoptosis, and 
inhibited tumor growth. 
Furthermore, these effects 
were mediated, at least in 
part, via regulation of the 
antiapoptotic factor survivin, 
which is a known facilitator 
of melanoma survival. 
Additionally, these effects were 
different in nontransformed 
cells, highlighting a specific 
role for this factor in 
melanoma cells and the overall 
complexity of BAP1 biology. 
See page 1089
On the Clock
The circadian clock controls DNA rep-
lication and repair, which are integral 
players in the skin’s response to UVR. 
Gaddameedhi and colleagues observed 
greater sunburn apoptosis, inflamma-
tory cytokine induction, and erythema in 
mouse skin following acute early-morning 
UVR exposure than following late-after-
noon exposure. A more robust DNA damage response, including activation of the Atr-
mediated DNA damage checkpoint and the p53 tumor suppressor, was also observed 
after morning exposure. In agreement with previous reports of higher susceptibility of 
mice to skin cancer following chronic morning UVR exposure, these findings support 
involvement of the circadian clock in the response to UVR. See page 1119
Understanding JunB
Reduced expression of JunB in 
psoriatic lesional epidermis sug-
gests that this transcription factor 
affects epidermal cell proliferation 
and inflammation. Accordingly, 
Zhang and colleagues showed 
that silencing of JunB resulted in 
increased cell proliferation and 
altered epidermal barrier function. 
ChIP-seq experiments revealed that JunB directly interacts with SQSTM1/p62 to sup-
press its transcription. This adaptor protein functions in NF-κB activation, which 
is essential for expression of psoriasis-related proinflammatory cytokines, which 
are induced upon JunB silencing. Together, these molecular findings indicate 
that JunB hypofunction impairs the epidermal barrier and suggest that SQSTM1 
and the NF-κB pathway are potential therapeutic targets for treating psoriasis. 
See page 1016
Positive for Pigmentation
The HMG–CoA reduc-
tase inhibitor simvastatin, 
which has been approved 
by the US Food and Drug 
Administration for hyper-
cholesterolemia, inhibits 
the IFN-γ-induced STAT1 
activation that is involved in 
the human depigmentation 
disease vitiligo. Coincidentally, high-dose simvastatin reportedly induced repigmenta-
tion in one vitiligo patient being treated for hypercholesterolemia. In a mouse model 
of vitiligo, Agarwal and colleagues demonstrated that simvastatin both prevented and 
reversed established depigmentation via a reduction of melanocyte-specific CD8+ T cells 
in the skin and the IFN-γ production by these cells. This positive therapeutic response 
warrants future investigation in human vitiligo patients and offers promise for a systemic 
treatment of this currently incurable autoimmune disease. See page 1080
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